Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823717 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL13219941 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL15216442 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL15083800 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL2399703 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL15153576 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL8620968 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL8586140 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL293897 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 | |
| SCHEMBL8814461 | 1.00 | FFAR4 (0.65) | FFAR4FFAR1L3MBTL1FAAHGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021086610-A1 | COMPOSITIONS AND METHODS OF USE | VERA BIOTECHNOLOGY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200046786-A1 | COMPOSITIONS AND METHODS OF USE | Shah, Kirit (US) | 2020-02-13 | — | — | US | disclosed |
| US-10478464-B2 | Compositions and methods of use | Shah, Kirit (US) | 2019-11-19 | — | — | US | disclosed |
| CN-102348461-B | Compositions and methods of use | VANAS ONCOLOGY | 2014-08-20 | — | — | CN | disclosed |
| EP-2381950-B1 | hydroxyhexadecanoic acid for the treatment of cancer | VANAS ONCOLOGY (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-2381950-B1 | hydroxyhexadecanoic acid for the treatment of cancer | VANAS ONCOLOGY (US) | 2013-11-13 | — | — | EP | disclosed |
| CN-102348461-A | Compositions and methods of use | VANAS ONCOLOGY | 2012-02-08 | — | — | CN | disclosed |
| EP-2381950-A2 | COMPOSITIONS AND METHODS OF USE | Vanas Oncology (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010083311-A2 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083311-A2 | COMPOSITIONS AND METHODS OF USE | VANAS ONCOLOGY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209543-A1 | COMPOSITIONS AND METHODS OF USE | MKI67, VHL, CCNC | FFAR4 4783/4885FFAR1 4689/4885L3MBTL1 1727/4885 |
| US-20200046786-A1 | COMPOSITIONS AND METHODS OF USE | MKI67, VHL, CCNC | FFAR4 4783/4885FFAR1 4689/4885L3MBTL1 1727/4885 |
| US-10478464-B2 | Compositions and methods of use | MKI67, VHL, CCNC | FFAR4 4783/4885FFAR1 4689/4885L3MBTL1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.